Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-dose PPI vs high-dose PPI vs vonoprazan-based quadruple therapy for Helicobacter pylori eradication
IRCT20140207016511N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vonoprazan in Helicobacter pylori infection (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Helicobacter pylori eradication. Started Sep 2025; status: completed.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20140207016511N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140207016511N2.